lymphoma
Conditions
Interventions
improved scheme IMRT:IMRT to dose 54.6Gy/26f
Sponsors
Dept. Radiation Oncology, Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: newly diagnosed ENKTL, or after short courses of inductive chemotherapy;the outcome after inductive chemotherapy should not be systemic PD; age:18-75years;Ann Arbor stage IE,or stage IIE with cervical lymph node involvement, primary site should be within upper aero-digestive tract;signed the consent form of this study;performance status of 0 to 2, with life expectation not less than 6 months;no previous history of radiotherapy, HIV test negative;Adequate hematologic function (eg, white blood cell = 3×10e9/l,neutrophils count =1.5×10e9/L, and platelet count= 100×10e9/L),renal function (eg, serum creatinine=1.5 mg/dL and creatinine clearance =50 mL minute), and hepatic function (e.g, total bilirubin= 2 times the upper limit of normal and aspartate and alanine transaminase levels = 3 times the upper limit of normal);with efficient economy to fulfill radiotherapy and the follow-up examinations.
Exclusion criteria
Exclusion criteria: mismatch the inclusion criteria; previous history of radiotherapy, especially within head and neck region; not completed the assigned radiotherapy; the treatment results of patients who quit the study due to side effect will not be included in effecacy evaluation, but the side effect should be included in toxicity analysis; lack of main clinical parameter, obvious insufficiency of follow-up materials; other clinical comorbidities that possibly influence treatment outcome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| locol-regional control; | — |
Secondary
| Measure | Time frame |
|---|---|
| toxic effects;progression-free survival (PFS);overall survival (OS); | — |
Countries
China
Contacts
Public ContactDr. Yujing ZHANG
Outcome results
None listed